Mizuho Securities Remains Neutral on Myriad Genetics (MYGN); Awaiting Reimbursement Progress
Tweet Send to a Friend
Mizuho Securities reiterated a Neutral rating and $42.00 price target on Myriad Genetics (NASDAQ: MYGN) following the company's 2Q earnings ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
